文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

新冠疫苗分剂次与全剂量加强针的免疫原性与反应原性:巴基斯坦非劣效随机双盲IV期临床试验

Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: A non-inferiority, randomized, double-blind, phase IV clinical trial in Pakistan.
PubMed 文献 · Vaccine · 2026-07-21

该IV期非劣效随机双盲试验在巴基斯坦18-60岁已完成基础免疫(Sinovac、AZD1222或自然感染)的成人中比较BNT162b2分剂次(1/3、1/2)与全剂量及全剂量Sinovac加强针的免疫原性与安全性。主要终点为第28天抗Spike IgG≥4倍升高,非劣效界值10%。Sinovac基础免疫者中,1/2和1/3剂量BNT162b2应答率(66.7%和70.5%)非劣于全剂量Sinovac(19.4%),但其他比较均未达非劣效;所有加强针耐受良好,无严重不良事件。

要点

  • Sinovac基础免疫者,1/2或1/3剂量BNT162b2第28天血清应答非劣于全剂量Sinovac。
  • 分剂次BNT162b2未非劣于全剂量BNT162b2,任何基础免疫组均未达非劣效界值。
  • 推荐Sinovac基础免疫者使用全剂量BNT162b2加强;若不可及可考虑分剂次,但避免再接种Sinovac。

核心结论

  • 分剂次BNT162b2仅对全剂量Sinovac非劣效,对全剂量BNT162b2未达非劣效。
  • 推荐Sinovac基础免疫者优先使用全剂量BNT162b2加强,避免再接种Sinovac。

研究设计与样本

  • 观察者盲、随机、IV期非劣效试验(2023年2月-2024年1月),在巴基斯坦信德省纳入18-60岁成人。
  • 共903名受试者接受加强针,按基础免疫(Sinovac、AZD1222或自然感染)分为10组,分别接种1/3、1/2或全剂量BNT162b2或全剂量Sinovac。
  • 随访6个月,第0、28、84、182天采血并评估安全性;主要终点为第28天抗Spike IgG≥4倍升高,非劣效界值10%。

主要发现

  • Sinovac基础免疫者中,1/2和1/3剂量BNT162b2第28天血清应答率分别为66.7%和70.5%,全剂量Sinovac为19.4%,达非劣效。
  • 上述组第84天和第182天应答率更高;其余非劣效比较均未达阈值。
  • 全剂量与分剂次BNT162b2在6个月内抗体水平相似;所有加强针耐受良好,无严重不良事件。

关键数值与推荐

  • 主要终点非劣效界值为10%,比较第28天抗Spike IgG≥4倍升高的比例。
  • Sinovac基础免疫者中,1/2和1/3剂量BNT162b2第28天应答率66.7%和70.5% vs 全剂量Sinovac 19.4%,达非劣效。

临床怎么用

  • Sinovac基础免疫者加强免疫应优先选用全剂量BNT162b2。
  • 若全剂量BNT162b2不可及,可考虑分剂次BNT162b2,但不应再接种Sinovac。
  • 分剂次策略需进一步研究抗体阈值以充分理解保护力。

局限性

  • 分剂次BNT162b2对全剂量BNT162b2未达非劣效,其他基础免疫组结果不支持分剂次。
  • 抗体阈值与保护力的关联尚未完全明确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated the immunogenicity and safety of fractional doses of SARS-CoV-2 booster vaccines compared to full doses in adults aged 18-60 primed with full series of Sinovac, AZD1222, or Natural Infection in Sindh, Pakistan. METHODS: This observer-blind, randomized phase IV non-inferiority trial (Feb 2023-Jan 2024) evaluated one-third, half, or full doses of BNT162b2, or full-dose Sinovac, in 10 arms based on primary vaccination. Participants were followed for 6 months with blood samples and safety assessments at days 0, 28, 84, and 182. The primary endpoint was a > 4-fold rise in anti-Spike IgG at day 28, comparing full and fractional doses using a 10% non-inferiority margin. FINDINGS: A total of 903 participants received boosters. In Sinovac-primed individuals, ½ and ⅓ dose BNT162b2 boosters showed non-inferior seroresponse at Day 28 compared to full-dose Sinovac (66.7% and 70.5% vs. 19.4%), with higher responses at Days 84 and 182. No other non-inferiority comparisons met the threshold. Antibody levels were similar between full and fractional BNT162b2 doses over six months. All boosters were well tolerated, with no serious adverse events. INTERPRETATION: Fractional BNT162b2 doses were non-inferior to the full Sinovac dose, but not to the full BNT162b2 dose in any priming group. Given these findings and considering the need for further research on antibody thresholds to fully understand the protection provided by fractional doses, we recommend using full BNT162b2 doses as boosters for those primed with Sinovac. If full BNT162b2 doses are not available, fractional BNT162b2 doses may be considered, but another Sinovac dose should be avoided.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hussain HS, Yousafzai MT, Iqbal J, et al. Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: A non-inferiority, randomized, double-blind, phase IV clinical trial in Pakistan. Vaccine. 2026. PMID: 42480193. doi:10.1016/j.vaccine.2026.128918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。